Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3782-3786

  Yao, Shijie ^a   Murali, Dhanabalan ^a   Seetharamulu, Peddaiahgari ^a   Haridas, Kochat ^a   Petluru, Pavankumar N V ^a   Reddy, Dasharatha G ^a   Hausheer, Frederick H ^a  

^a BioNumerik Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DOUBLE STRANDED DNA; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; DNA BINDING; DNA SEQUENCE; DRUG DNA BINDING; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANTINEOPLASTIC AGENTS; DNA; DNA TOPOISOMERASES, TYPE I; DNA, SINGLE-STRANDED; HYDROGEN-ION CONCENTRATION; LACTONES; MAGNETIC RESONANCE SPECTROSCOPY; TOPOTECAN;

EID: 0032170499     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., and Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888-3890, 1966.
2. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046-1048, 1989.
3. Potmesil, M. Camptothecin: from bench research to hospital wards. Cancer Res., 54: 1431-1439, 1994.
4. Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. (Bethesda), 85: 271-287, 1993.
5. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst. (Bethesda), 86: 836-842, 1994.
6. Wall, M. E., Wani, M. C., Nicholas A. W., Manikumar, G., Tele, C., Moore, L., Truesdale, A., Leitner, P. L., and Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2689-2700, 1993.
7. Juzzio, M. J., Besterman, J. M., Emerson, D. L, Evans, M. G., Lackey, K., Leitner, P. L., McIntyre, G., Morton, B., Myers, P. L., Peel, M., Sisco, J. M., Sternbach, D. D., Tong, W-Q., Truesdale, A., Uehling, D. E., Vuong, A., and Yates, J. Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I. J. Med. Chem., 38: 395-401, 1995.
8. Pantazis, P., Giovanella, B. C., and Rothenberg, M. L. (eds.). The camptothecins: from discovery to the patient. Ann. N. Y. Acad. Sci., 803, 1996.
9. Hausheer, F., Haridas, K., Zhao, M., Murali, D., Seetharamulu, P., Yao, S., Reddy, D., Pavankumar, P., Saxe, J., Quili, H., and Rustum, Y. Karenitecins: a novel, potent class of oral highly lipophilic topo I inhibitors. Proc. Am. Assoc. Cancer Res., 38: 227, 1997.
10. Hausheer, F., Haridas, K., Zhao, M., Murali, D., Seetharamulu, P., Yao, S., Reddy, D., Pavankumar, P., Wu, M., Saxe, J., Huang, Q., and Rustum, Y. Karenitecins (part II). A novel class of orally active highly lipophilic topoisomerase I inhibitors. Proc. Am. Assoc. Cancer Res., 39: 420, 1998.
11. Hsiang, Y-H., Hertzberg, R. P., Hecht, S. M., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873-14878, 1985.
12. Hertzberg, R. P., Caranfa, M. J., and Hecht, S. M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629-4638, 1989.
13. Champoux, J. J., and Aronoff, R. The effects of camptothecin on the reaction and the specificity of the wheat germ type I topoisomerase. J. Biol. Chem., 264: 1010-1015, 1989.
14. Kjeldsen, E., Mollerup, S., Thomsen, B., Bonven, B., Bolund, L., and Westergaard, O. Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage. J. Mol. Biol., 202: 333-342, 1988.
15. Thomsen, B., Mollerup, S., Bonven, B. J., Frank, R., Blocker, H., Nielsen, O. F., and Westergaard, O. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin. EMBO J., 6: 1817-1823, 1987.
16. Hertzberg, R. P., Busby, R. W., Caranfa, M. J., Holden, K. G., Johnson, R. K., Hecht, S. M., and Kingsbury, W. D. Irreversible trapping of the DNA-topoisomerase I covalent complex. J. Biol. Chem., 265: 19287-19295, 1990.
17. Fukada, M. Action of camptothecin and its derivatives on deoxyribonucleic acid. Biochem. Pharmacol., 34: 1225-1230, 1985.
18. Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K. W., and Pommier, Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry, 32: 8955-8962, 1993.
19. Yang, D., Strode, J. T., Spielmann, H. P., Wang, A. H-J., and Burke, T. G. DNA interactions of two clinical camptothecin drugs stabilize their active lactone forms. J. Am. Chem. Soc., 120: 2979-2980, 1998.
20. Underberg, W. J. M., Goossen, R. M. J., Smith, B. R., and Beijnen, J. H. Equilibrium kinetics of the new experimental antitumor compound SK&F1048-A in aqueous solution. J. Pharm. Biomed. Anal., 8: 681-683, 1990.
21. Burke, T. G., and Mi, Z. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. Med. Chem., 37: 40-46, 1994.
22. Wall, M. E., and Vani, M. C. Antineoplastic agents from plants. Annu. Rev. Pharmacol. Toxicol., 17: 117-132, 1977.
23. Wani, M. C., Ronman, P. E., Lindley, J. T., and Wall, M. E. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogues. J. Med. Chem., 23: 554-560, 1980.
24. Hertzberg, R. P., Caranfa, M. J., Holden, K. G., Jakas, D. R., Gallagher, G., Mattern, M. R., Mong, S-M., Bartus, J. O., Johnson, R. K., and Kingsbury, W. D. Modification of the hydroxyl lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J. Med. Chem., 32: 715-720, 1989.
25. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Kirschenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res., 49: 4385-4389, 1989.
26. Sawada, S., Okajima, S., Aiyama, R., Nokata, K., Furuta, T., Yokokura, T., Sugino, E., Yamaguchi, K., and Miyasaka, T. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull., 39: 1446-1454, 1991.
27. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98-107, 1991.
28. Yao, S. Intercalator-nucleic acid interaction: physical and molecular modeling studies (Ph.D. Thesis). Georgia State University, Atlanta, GA, 1993.
29. Lombardy, R. L., Tanious, F. A., Ramachandran, K., Tidwell, R. R., and Wilson, W. D. Synthesis, and DNA interactions of benzimidazole dications which have activity against opportunistic infections. J. Med. Chem., 39: 1452-1462, 1996.
30. Chourpa, I., Riou, J-F., Millot, J-M., Pommier, Y., and Manfait, M., Modulation in kinetics of lactone ring hydrolysis of camptothecins upon interaction with topoisomerase I cleavage sites on DNA. Biochemistry, 37: 7284-7291, 1998.